GLPwatch
Exenatide implant therapy in diabetes.
J Pak Med Assoc · 2018
Last updated 2026-05-28ITCA 650 is an implantable device that releases a steady dose of the GLP-1 drug exenatide under the skin. In studies, it has been used to help manage type 2 diabetes, though the abstract does not provide specific participant numbers or effectiveness percentages.
AI summary of the abstract below.
| Journal | J Pak Med Assoc, 2018 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.09 |
| NIH percentile | 7 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
This review describes a recent advance in diabetes pharmacotherapeutics and drug delivery. ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exenatide, when inserted subcutaneously. The article discusses the pharmacodynamics and pharmacokinetics of ITCA 650, and suggests how it's benefits can be utilized in clinical practice. It lists the advantages and limitations of the device, and shares tips for its rational use in type 2 diabetes care.
Verbatim abstract via PubMed 30317359 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.